<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126511</url>
  </required_header>
  <id_info>
    <org_study_id>AlphaStim</org_study_id>
    <nct_id>NCT05126511</nct_id>
  </id_info>
  <brief_title>Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19</brief_title>
  <official_title>Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19 - a Randomised Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schön Klinik Berchtesgadener Land</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schön Klinik Berchtesgadener Land</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effect of cranial electrotherapy stimulation&#xD;
      (CES), for one hour a day over 3 weeks pulmonary rehabilitation (PR) program on symptoms of&#xD;
      anxiety in post-Covid patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patients recovering from Covid-19 develop sequelae related to the disease. In addition&#xD;
      to lung issues, symptoms of Post-Covid/Long-Covid Syndrome include fatigue, brain fog,&#xD;
      amyosthenia, insomnia, anxiety and depression. These symptoms play a major role in post-Covid&#xD;
      patients recovery.&#xD;
&#xD;
      CES (Cranial electrotherapy stimulation) is a non-invasive therapy using low intensity&#xD;
      alternating current applied through electrodes attached to the ear lobe.&#xD;
&#xD;
      CES has been used to improve the condition of non covid patients suffering from depression,&#xD;
      anxiety, fatigue and cognitive disabilities. This is thought to be due to a change in&#xD;
      electric waves of the brain with an increase of alpha-waves and a decrease of beta- and&#xD;
      delta-waves, as well as a change of concentration of neurotransmitters, e.g. beta-endorphin&#xD;
      or serotonin.&#xD;
&#xD;
      Therefore, this study aims to investigate the effect of CES in addition to normal PR,&#xD;
      compared to PR alone on symptoms (e.g. anxiety) in post-Covid patients.&#xD;
&#xD;
      Hypothesis: Three weeks of PR including daily use of CES for one hour will have a positive&#xD;
      effect on symptoms of anxiety.&#xD;
&#xD;
      Trial: 40 patients post-Covid reffered to inpatient PR will be recruited and allocated to one&#xD;
      of two different groups. Group1: Anxious participants, Group 2: Non anxious participants.&#xD;
      Within groups particpants will be randomized to intervention or control/sham. Intervention&#xD;
      group will be using a functional device, and the other using a non-functional, SHAM device.&#xD;
&#xD;
      Anxiety is evaluated using the Beck anxiety inventory on admission and at discharge from PR.&#xD;
&#xD;
      Questionnaires to evaluate fatigue, depression and insomnia are the Fatigue Assessment Scale,&#xD;
      PHQ-9, PSQI).&#xD;
&#xD;
      A diary will be kept by each participant with a log of general health and mood over the PR&#xD;
      program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of symptoms of anxiety during intervention</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>Comparison of the Beck Anxiety Inventory pre and post pulmonary rehabilitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insomnia during intervention</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>Comparison of the PSQI questionnaire pre and post pulmonary rehabilitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue during intervention</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>Comparison of the FAS questionnaire pre and post pulmonary rehabilitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression during intervention</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>Comparison of the PHQ-9 questionnaire pre and post pulmonary rehabilitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of general condition/ perceived well-being of the patient</measure>
    <time_frame>Day 1 until Day 21</time_frame>
    <description>Evaluation of the diary kept by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effectiveness of device</measure>
    <time_frame>Day 21</time_frame>
    <description>Evaluation of the diary kept by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort while using the device</measure>
    <time_frame>Day 21</time_frame>
    <description>Evaluation of the diary kept by the patient</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>POST-Covid 19</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Post-Covid patients, anxious, functional device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Applitation of 100µA CES for one hour per day to anxious patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Covid patients, anxious, Sham</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of Sham CES for one hour per day by anxious patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Covid patients, non anxious, functional device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of 100µA CES for one hour per day to non anxious patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Covid patients, non anxious, Sham</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of Sham CES for one hour per day by non anxious patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Application of CES via ear clips</intervention_name>
    <description>Use of 100µA CES for one hour per day over PR program</description>
    <arm_group_label>Post-Covid patients, anxious, functional device</arm_group_label>
    <arm_group_label>Post-Covid patients, non anxious, functional device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham: No application of CES via ear clips</intervention_name>
    <description>Use of Sham CES for one hour per day over PR programm</description>
    <arm_group_label>Post-Covid patients, anxious, Sham</arm_group_label>
    <arm_group_label>Post-Covid patients, non anxious, Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group with anxiety:&#xD;
&#xD;
          -  high Beck Anxiety Inventory Score&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  post SARS-CoV-2 infection&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
        Group without anxiety:&#xD;
&#xD;
          -  low Beck Anxiety Inventory Score&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  post SARS-CoV-2 infection&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acitve implants (cardiac pacemaker,...)&#xD;
&#xD;
          -  pregnancy, lactation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas R. Koczulla, Prof. Dr. med.</last_name>
    <phone>0049-8652-932730</phone>
    <email>rkoczulla@schoen-klinik.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tessa Schneeberger, MSc</last_name>
    <phone>08652932730</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Berchtesgadener Land, Schön Kliniken</name>
      <address>
        <city>Schönau Am Königssee</city>
        <state>Bavaria</state>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tessa Schneeberger, MSc</last_name>
      <phone>0049 - 8652 - 932730</phone>
      <email>tschneeberger@schoen-klinik.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Schön Klinik Berchtesgadener Land</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Andreas Rembert Koczulla</investigator_full_name>
    <investigator_title>Head of Pneumological Department Affiliation: Schön Klinik Berchtesgadener Land</investigator_title>
  </responsible_party>
  <keyword>Long-Covid/ Post-Covid</keyword>
  <keyword>CES</keyword>
  <keyword>fatigue</keyword>
  <keyword>insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

